BioWorld

April 11, 2007

View Archived Issues

Erbitux Misses In Pancreatic Cancer, Dropping ImClone

Shares in ImClone Systems Inc. took a 6.4 percent dip on word that Erbitux (cetuximab) missed the primary endpoint in a Phase III pancreatic cancer study, a backslide that follows a month of significant gains. (BioWorld Today) Read More

Ascenta Raises $50M For Apoptosis Phase II Trials

Read More

Entereg Data Show Heart Risks, Adolor Plummets

Read More

Inhibitex Acquiring FermaVir In All-Stock Deal Valued At $19M

Read More

Biosite To Consider IMI's Offer Over Rival Beckman

Read More

Advancis Raising $24M To Get Amoxicillin Pulsys To Market

Read More

Other News To Note

Read More

Clinic Roundup

Read More